Results 1 to 10 of about 78,032 (168)

Efficacy and Safety of Rituximab in Connective Tissue Disease-Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy. [PDF]

Int J Rheum Dis
ABSTRACT Introduction This study examined the efficacy and safety of Rituximab (RTX) treatment in connective tissue disease (CTD)‐associated thrombocytopenic purpura (TTP) and thrombotic microangiopathy (TMA), using historical controls as comparators.
Ohkubo N, Nakayamada S, Fukuyo S, Miyazaki Y, Inoue Y, Tanaka H, Todoroki Y, Tanaka Y.   +7 more
europepmc   +2 more sources

Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature

Journal of Medical Case Reports, 2018
Background Incidences of immune thrombocytopenic purpura occur in 1 in every 1000–10,000 pregnancies accounting for 3% of all thrombocytopenic pregnancies.
Naser Al-Husban, Oqba Al-Kuran
doaj   +2 more sources

How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. [PDF]

Br J Haematol
The use of rituximab as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP) is the current standard of care. However, for patients refractory to rituximab or for those with contraindication, further treatment guidelines are scarce.
Weisinger J, Fadlallah J, Joly B, Veyradier A, Coppo P.   +4 more
europepmc   +2 more sources

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura

Haematologica, 2016
Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13.
Wenjing Cao, Huy P. Pham, Lance A. Williams, Jenny McDaniel, Rance C. Siniard, Robin G. Lorenz, Marisa B. Marques, X. Long Zheng   +7 more
doaj   +2 more sources

Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura

Haematologica, 2019
Immune-mediated thrombotic thrombocytopenic purpura is characterized by severe thrombocytopenia and microangiopathic hemolytic anemia. It is primarily caused by immunoglobin G type autoantibodies against ADAMTS13, a plasma metalloprotease that cleaves ...
Elizabeth M. Staley, Wenjing Cao, Huy P. Pham, Chong H. Kim, Nicole K. Kocher, Lucy Zheng, Radhika Gangaraju, Robin G. Lorenz, Lance A. Williams, Marisa B. Marques, X. Long Zheng   +10 more
doaj   +2 more sources

Novel Mutation of Upshaw-Schulman Syndrome Associated with Coarctation of Aorta in Palestinian Child [PDF]

Ķazaķstannyṇ Klinikalyķ Medicinasy, 2020
Upshaw-Schulman syndrome is a rare inherited form of thrombotic thrombocytopenic purpura disease caused by deficiency of ADAMTS13 and reversible by fresh frozen plasma infusions.
Mahdi Zaid, Sultan Musleh, Tahani Sarrawi, Maysa Alawneh, Reem Sawafta, Honood AbuRas   +5 more
doaj   +1 more source

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management

Journal of Clinical Medicine, 2021
Thrombotic thrombocytopenic purpura (TTP) is a rare thrombotic microangiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and ischemic end organ injury due to microvascular platelet-rich thrombi.
S. Sukumar, B. Lämmle, S. Cataland
semanticscholar   +1 more source

Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature

Journal of Medical Case Reports, 2023
Background Immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura are both causes of thrombocytopenia. Recognizing thrombotic thrombocytopenic purpura is crucial for subsequent treatment and prognosis.
Hung-Chen Lin, Jinxiang Huang, Jing Huang, Li-Jun Zhang, Xiao-Wu Yin, Jian-Cheng Yang, Xiao-Yan Huang   +6 more
doaj   +1 more source

Coexistence of thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in an Asian woman: a case report

Journal of International Medical Research, 2022
A 33-year-old Chinese woman with a history of immune thrombocytopenic purpura presented with heavy menstrual bleeding. She was found to have thrombocytopenia, plasma ADAMTS13 activity of 0%, and positivity for the plasma ADAMTS13 inhibitor.
Hangping Ge, Zhan Shi, Zhiyin Zheng, Qiuping Zhu, Lili Hong, Yu Zhang, Jianping Shen, Shu Deng   +7 more
doaj   +1 more source

Case Report: Rabies Vaccine-Induced Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus

Frontiers in Immunology, 2022
For patients with autoimmune diseases, vaccination is controversial. The use of vaccination in patients with autoimmune diseases is controversial. There are many reports of secondary thrombotic thrombocytopenic purpura cases after various vaccinations ...
Yanming Cui, Jianbo Wei, Xiang Peng
doaj   +1 more source